ZymoGenetics Begins Phase 2 Analysis In Renal Cell Cancer Evaluating IL-21 Comb

Healthcare Professional: General Public: ZymoGenetics, Inc. NASDAQ:ZGEN) announced that the company has initiated Episode 2 testing of Interleukin 21 (IL-21) in combination with Nexavar(R) (sorafenib) tablets in patients with modern renal chamber cancer.

The Phase 2 study is part of a Phase 1 2 clinical check and will examine patients treated with the maximum tolerated potion identified in the recently completed Leaf 1 dose escalation phase.

We're encouraged by the fruit of the Page 1 parcel of this trial and are convinced that IL-21 in combination with Nexavar deserves further probation in renal apartment cancer," said Nicole Onetto, M.D., Senior Vice President and Chief Medical Officer of ZymoGenetics. In Event 2, we'll continue to evaluate the tolerability and anti-tumor activity of this combination therapy in patients with dilatory stage renal cell cancer."

The leading objective of the open label multi-center Phase 2 glance at is to characterize aegis of IL-21 with Nexavar at the recommended dose; a secondary objective is to assess anti-tumor activity, which will be assessed by evaluating tumour response and circuit free survival. The trial is expected to enroll approximately 30 patients.

The recite is evaluating the combination in patients with pleasant cell carcinoma, which accounts for 85% of all renal cell tumors.

Results from the Phase 1 Trial with IL-21 and Nexavar Interim results from the Sheet 1 trial of IL-21 in combination with Nexavar in patients with renal cell cancer were presented in October 2007 at the AACR-NCI-EORTC International Conference.

That data indicated that the combination of IL-21 and Nexavar is well tolerated, with a toxicity profile collateral to published toxicities of each agent alone. Opening evidence of anti-tumor activity was also documented in the majority of the patients treated in Period 1. There will be an estimated 51,190 contemporary crate of renal cell carcinoma in the U.S. 2007.

It is estimated that renal cubicle carcinoma testament result in approximately 19,600 deaths in the U.S. Renal cell carcinoma render a reckoning for approximately 2% of cancers world wide. There is a clear need for new and improved therapies for renal cell cancer.

IL-21 in Set with Tyrosine Kinase Inhibitors Because tyrosine kinase inhibitors (TKIs) such as Nexavar and Sutent® (Sunitinib) inhibit the growth of tumor cells and act on the underlying vasculature, and IL-21 activates the unaffected method to target slaughter of tumor cells, the two remedial programme may provide additive effects.

Treatment with a TKI may make cancer cells more sensitive to natural killer or T cell mediated killing after activation with IL-21.

Preclinical analysis conducted by ZymoGenetics of TKIs and IL-21 found that IL-21 had additive anti-tumor outcome when combined with a TKI in a renal cell cancer model. Previous clinical studies with IL-21 alone shown that IL-21 is an full cytokine that can be administered in an outpatient regimen.

Effect from a Stage 1 study presented at the American Homeland of Clinical Oncology (ASCO) 2006 annual meeting showed that IL-21 administration was tolerable in an outpatient setting and reductions in tumor size were observed in several patients. Available clinical data aid further clinical subject of IL-21 as a new restorative go-between for the treatment of cancer.

Approximately IL-21 Endogenous IL-21 has potent organic activity in regulating key classes of immune cells, including cytotoxic T cells and commonplace killer cells. These cell class frisk important roles in eliminating malignant and infected cells.

Based upon the knack of IL-21 to hold back tumor growth in a number of being models, ZymoGenetics is developing a recombinant figure of IL-21 representing the treatment of cancer, initially in metastatic melanoma and renal cell carcinoma and has retained commercialization rights championing IL-21 in North America. The company licensed commercialization rights outside of North America to Novo Nordisk A S. About ZymoGenetics ZymoGenetics creates narration protein drugs with the potential to significantly help patients fight their diseases.

The business is developing a contrasting pipeline of product aspirant that are moving into and through clinical development. These office-seeker chiefly span a wide array of clinical opportunities that include bleeding, autoimmune and viral diseases and cancer.

ZymoGenetics intends to commercialize these product candidates through interior development, collaborations with partners, and out-licensing of patents from its extensive patent portfolio.